Identify and Validate Innovative Peptides for the Treatment of Obesity
The Pharma Data
MARCH 2, 2021
Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
Let's personalize your content